Early postoperative decrease of albumin is an independent predictor of major complications after oncological esophagectomy: A multicenter study.


Journal

Journal of surgical oncology
ISSN: 1096-9098
Titre abrégé: J Surg Oncol
Pays: United States
ID NLM: 0222643

Informations de publication

Date de publication:
Feb 2021
Historique:
received: 05 10 2020
revised: 07 11 2020
accepted: 14 11 2020
pubmed: 9 12 2020
medline: 5 3 2021
entrez: 8 12 2020
Statut: ppublish

Résumé

Serum albumin perioperative decrease (∆Alb) may reflect the magnitude of the physiological stress induced by surgery. Studies highlighted its value to predict adverse postoperative outcomes, but data in esophageal surgery are scant. This study aimed to investigate the role of ∆Alb to predict major complications after esophagectomy for cancer. Multicenter retrospective study conducted in five high-volume centers, including consecutive patients undergoing an esophagectomy for cancer between 2006 and 2017. Patients were randomly assigned to a training (n = 696) and a validation (n = 350) cohort. Albumin decrease was calculated on postoperative day 1 and defined as ΔAlb. The primary endpoint was major complications according to Clavien classification. In the training cohort, esophagectomy induced a rapid drop of albumin. Cut-off of ΔAlb was established at 11 g/L and allowed to distinguish patients with adverse outcomes. On multivariable analysis, ΔAlb was identified as an independent predictor of major complications (OR, 1.06; 95% CI, 1.01-1.11; p = .014). Higher BMI and laparoscopy were associated with lower ΔAlb. Analysis of the validation cohort provided consistent findings. ΔAlb appeared as a promising biomarker after oncological esophagectomy, allowing prediction of potential adverse outcomes.

Sections du résumé

BACKGROUND AND OBJECTIVES OBJECTIVE
Serum albumin perioperative decrease (∆Alb) may reflect the magnitude of the physiological stress induced by surgery. Studies highlighted its value to predict adverse postoperative outcomes, but data in esophageal surgery are scant. This study aimed to investigate the role of ∆Alb to predict major complications after esophagectomy for cancer.
METHODS METHODS
Multicenter retrospective study conducted in five high-volume centers, including consecutive patients undergoing an esophagectomy for cancer between 2006 and 2017. Patients were randomly assigned to a training (n = 696) and a validation (n = 350) cohort. Albumin decrease was calculated on postoperative day 1 and defined as ΔAlb. The primary endpoint was major complications according to Clavien classification.
RESULTS RESULTS
In the training cohort, esophagectomy induced a rapid drop of albumin. Cut-off of ΔAlb was established at 11 g/L and allowed to distinguish patients with adverse outcomes. On multivariable analysis, ΔAlb was identified as an independent predictor of major complications (OR, 1.06; 95% CI, 1.01-1.11; p = .014). Higher BMI and laparoscopy were associated with lower ΔAlb. Analysis of the validation cohort provided consistent findings.
CONCLUSIONS CONCLUSIONS
ΔAlb appeared as a promising biomarker after oncological esophagectomy, allowing prediction of potential adverse outcomes.

Identifiants

pubmed: 33289149
doi: 10.1002/jso.26317
doi:

Substances chimiques

Biomarkers, Tumor 0
Serum Albumin 0

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

462-469

Informations de copyright

© 2020 Wiley Periodicals LLC.

Références

Pennathur A, Gibson MK, Jobe BA, Luketich JD. Oesophageal carcinoma. Lancet. 2013;381(9864):400-412.
Fitzmaurice C, Dicker D, Pain A, et al. The global burden of cancer 2013. JAMA Oncol. 2015;1(4):505-527.
Lagergren J, Smyth E, Cunningham D, Lagergren P. Oesophageal cancer. Lancet. 2017;390(10110):2383-2396.
Lordick F, Mariette C, Haustermans K, et al. Oesophageal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl 5):v50-v57.
Biere SS, van Berge Henegouwen MI, Maas KW, et al. Minimally invasive versus open oesophagectomy for patients with oesophageal cancer: a multicentre, open-label, randomised controlled trial. Lancet. 2012;379(9829):1887-1892.
Mariette C, Markar SR, Dabakuyo-Yonli TS, et al. Hybrid minimally invasive esophagectomy for esophageal cancer. N Engl J Med. 2019;380(2):152-162.
Fransen LFC, Berkelmans GHK, Asti E, et al. The effect of postoperative complications after minimally invasive esophagectomy on long-term survival: an International Multicenter Cohort Study [published online ahead of print January 14, 2020]. Ann Surg.
Markar S, Gronnier C, Duhamel A, et al. The impact of severe anastomotic leak on long-term survival and cancer recurrence after surgical resection for esophageal malignancy. Ann Surg. 2015;262(6):972-980.
Liou DZ, Serna-Gallegos D, Mirocha J, Bairamian V, Alban RF, Soukiasian HJ. Predictors of failure to rescue after esophagectomy. Ann Thorac Surg. 2018;105(3):871-878.
Labgaa I, Demartines N, Hubner M. Biomarkers capable to early predict postoperative complications: the grail. Ann Surg. 2017;266(6):e91-e92.
Labgaa I, Demartines N, Hubner M. Serum albumin: a promising biomarker to anticipate postoperative complications. Dis Colon Rectum. 2017;60(9):e616.
Hübner M, Mantziari S, Demartines N, Pralong F, Coti-Bertrand P, Schäfer M. Postoperative albumin drop is a marker for surgical stress and a predictor for clinical outcome: a pilot study. Gastroenterol Res Pract. 2016;2016:8743187-8743188.
Labgaa I, Joliat GR, Demartines N, Hübner M. Serum albumin is an early predictor of complications after liver surgery. Dig Liver Dis. 2016;48(5):559-561.
Ryan AM, Hearty A, Prichard RS, Cunningham A, Rowley SP, Reynolds JV. Association of hypoalbuminemia on the first postoperative day and complications following esophagectomy. J Gastrointest Surg. 2007;11(10):1355-1360.
Labgaa I, Joliat GR, Kefleyesus A, et al. Is postoperative decrease of serum albumin an early predictor of complications after major abdominal surgery? A prospective cohort study in a European centre. BMJ Open. 2017;7(4):e013966.
Liu ZJ, Ge XL, Ai SC, et al. Postoperative decrease of serum albumin predicts short-term complications in patients undergoing gastric cancer resection. World J Gastroenterol. 2017;23(27):4978-4985.
Mantziari S, Hübner M, Coti-Bertrand P, Pralong F, Demartines N, Schäfer M. A novel approach to major surgery: tracking its pathophysiologic footprints. World J Surg. 2015;39(11):2641-2651.
Babic B, Tagkalos E, Gockel I, et al. C-reactive protein levels after esophagectomy are associated with increased surgical trauma and complications. Ann Thorac Surg. 2020;109:1574-1583.
Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205-213.
Slankamenac K, Graf R, Barkun J, Puhan MA, Clavien PA. The comprehensive complication index: a novel continuous scale to measure surgical morbidity. Ann Surg. 2013;258(1):1-7.
Hastie T, Tibshirani R, Friedman J. The Elements of Statistical Learning. Springer Series in Statistics. New York: Springer; 2001:222.
Scarpa M, Cavallin F, Saadeh LM, et al. Hybrid minimally invasive esophagectomy for cancer: impact on postoperative inflammatory and nutritional status. Dis Esophagus. 2016;29(8):1064-1070.
Gordon AC, Cross AJ, Foo EW, Roberts RH. C-reactive protein is a useful negative predictor of anastomotic leak in oesophago-gastric resection. ANZ J Surg. 2018;88(3):223-227.
Miki Y, Toyokawa T, Kubo N, et al. C-reactive protein indicates early stage of postoperative infectious complications in patients following minimally invasive esophagectomy. World J Surg. 2017;41(3):796-803.
Muneoka Y, Ichikawa H, Kosugi S, et al. Hyperbilirubinemia predicts the infectious complications after esophagectomy for esophageal cancer. Ann Med Surg. 2019;39:16-21.
Nomura S, Tsujimoto H, Aosasa S, et al. Impact of angiotensin-converting enzyme 2 levels on postoperative pneumonia after esophagectomy. J Surg Res. 2018;224:200-206.

Auteurs

Ismail Labgaa (I)

Department of Visceral Surgery, Lausanne University Hospital (CHUV), University of Lausanne (UNIL), Switzerland.

Styliani Mantziari (S)

Department of Visceral Surgery, Lausanne University Hospital (CHUV), University of Lausanne (UNIL), Switzerland.

Maxime Genety (M)

Department of Digestive and Oncological Surgery, University of Lille, Claude Huriez University Hospital, Lille, France.

Jessie A Elliott (JA)

Department of Surgery, Trinity Translational Medicine Institute, St. James's Hospital, Dublin, Ireland.

Satoshi Kamiya (S)

Department of Clinical Science, Intervention and Technology (CLINTEC), Division of Surgery, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.

Marianne C Kalff (MC)

Department of Surgery, Amsterdam University Medical Centers, Location Academic Medical Center, University of Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands.

Michaël Winiker (M)

Department of Visceral Surgery, Lausanne University Hospital (CHUV), University of Lausanne (UNIL), Switzerland.

Jérôme Pasquier (J)

Center for Primary Care and Public Health, University of Lausanne, Lausanne, Switzerland.

Pierre Allemann (P)

Department of Visceral Surgery, Lausanne University Hospital (CHUV), University of Lausanne (UNIL), Switzerland.

Marguerite Messier (M)

Department of Digestive and Oncological Surgery, University of Lille, Claude Huriez University Hospital, Lille, France.

Mark I van Berge Henegouwen (MI)

Department of Surgery, Amsterdam University Medical Centers, Location Academic Medical Center, University of Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands.

Magnus Nilsson (M)

Department of Clinical Science, Intervention and Technology (CLINTEC), Division of Surgery, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.

John V Reynolds (JV)

Department of Surgery, Trinity Translational Medicine Institute, St. James's Hospital, Dublin, Ireland.

Guillaume Piessen (G)

Department of Digestive and Oncological Surgery, University of Lille, Claude Huriez University Hospital, Lille, France.

Martin Hübner (M)

Department of Visceral Surgery, Lausanne University Hospital (CHUV), University of Lausanne (UNIL), Switzerland.

Markus Schäfer (M)

Department of Visceral Surgery, Lausanne University Hospital (CHUV), University of Lausanne (UNIL), Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH